Back to Top
  • Journal of Ocular Pharmacology and Therapeutics is pleased to announce that Dr. Uday Kompella, Professor of Pharmaceutical Sciences, Ophthalmology and Bioengineering, University of Colorado, Anschutz Medical Campus, will be assuming the role as Editor-in-Chief of Journal of Ocular Pharmacology and Therapeutics on April 1, 2021 taking over the mantle from W. Daniel Stamer, PhD, FARVO, Joseph A. C. Wadsworth Professor of Ophthalmology, Professor of Biomedical Engineering, Duke University. We warmly thank and acknowledge Dr. Stamer for his exceptional vision, leadership, and commitment to the journal for the many years he served as Editor-in-Chief of the publication.

Aims & Scope

Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders.

Journal of Ocular Pharmacology and Therapeutics coverage includes:

  • Glaucoma
  • Cataracts
  • Retinal degeneration
  • Ocular infection, trauma, and toxicology
  • Ocular drug delivery and biotransformation
  • Ocular pharmacotherapy/clinical trials
  • Ocular inflammatory and immune disorders
  • Gene and cell-based therapies
  • Ocular metabolic disorders
  • Ocular ischemia and blood flow
  • Proliferative disorders of the eye
  • Eyes on Drug Discovery - written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA

Journal of Ocular Pharmacology and Therapeutics is under the editorial leadership of Uday Kompella, PhD, University of Colorado Anschutz Medical Campus; and his Associate Editors: Michael Niesman, PhD, MingSight Pharmaceuticals, Retinal Pharmacology; Naj A. Sharif, PhD, FARVO, Santen Incorporated, Pre-clinical Ocular Pharmacology; Linda D. Hazlett, PhD, Wayne State University School of Medicine, Ocular Surface Pharmacology; Carol B. Toris, PhD, University of Nebraska Medical Center, Aqueous Humor Dynamics; and an editorial board of leading experts. View the entire editorial board.

Audience: Academic, industry, and government scientists, ophthalmologists, optometrists, clinical and research trainees, and many others


  • PubMed/MEDLINE
  • PubMed Central
  • Current Contents®/Life Sciences
  • Biological Abstracts
  • BIOSIS Previews
  • Journal Citation Reports/Science Edition
  • Prous Science Integrity®
  • Derwent Drug File
  • EMBASE/Excerpta Medica
  • Scopus
  • Chemical Abstracts
  • ProQuest databases
  • CAB Abstracts
  • Global Health
  • Derwent Publications Abstracts
  • BenchSci
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.